WO2011064797A3 - Controlled release pharmaceutical compositions of galantamine - Google Patents

Controlled release pharmaceutical compositions of galantamine Download PDF

Info

Publication number
WO2011064797A3
WO2011064797A3 PCT/IN2010/000767 IN2010000767W WO2011064797A3 WO 2011064797 A3 WO2011064797 A3 WO 2011064797A3 IN 2010000767 W IN2010000767 W IN 2010000767W WO 2011064797 A3 WO2011064797 A3 WO 2011064797A3
Authority
WO
WIPO (PCT)
Prior art keywords
galantamine
pharmaceutical compositions
controlled release
release pharmaceutical
release
Prior art date
Application number
PCT/IN2010/000767
Other languages
French (fr)
Other versions
WO2011064797A2 (en
Inventor
Ashok Omray
Sandhya Rajendra Shenoy
Harish Tulsidutt Bhatt
Original Assignee
Usv Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Limited filed Critical Usv Limited
Priority to EP10812951.1A priority Critical patent/EP2503996A2/en
Priority to BR112012012766A priority patent/BR112012012766A2/en
Priority to CA2781826A priority patent/CA2781826A1/en
Publication of WO2011064797A2 publication Critical patent/WO2011064797A2/en
Publication of WO2011064797A3 publication Critical patent/WO2011064797A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed are controlled release pharmaceutical compositions of Galantamine comprising a plurality of matrix mini tablets comprising Galantamine or its pharmaceutically acceptable salt and at least one release modifying agent. Said compositions are characterized by the absence of release rate modifying coating and/or absence of an immediate release portion of the Galantamine.
PCT/IN2010/000767 2009-11-26 2010-11-26 Controlled release pharmaceutical compositions of galantamine WO2011064797A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10812951.1A EP2503996A2 (en) 2009-11-26 2010-11-26 Controlled release pharmaceutical compositions of galantamine
BR112012012766A BR112012012766A2 (en) 2009-11-26 2010-11-26 controlled release galantamine pharmaceutical compositions
CA2781826A CA2781826A1 (en) 2009-11-26 2010-11-26 Controlled release pharmaceutical compositions of galantamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2736/MUM/2009 2009-11-26
IN2736MU2009 2009-11-26

Publications (2)

Publication Number Publication Date
WO2011064797A2 WO2011064797A2 (en) 2011-06-03
WO2011064797A3 true WO2011064797A3 (en) 2012-04-12

Family

ID=44067021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000767 WO2011064797A2 (en) 2009-11-26 2010-11-26 Controlled release pharmaceutical compositions of galantamine

Country Status (4)

Country Link
EP (1) EP2503996A2 (en)
BR (1) BR112012012766A2 (en)
CA (1) CA2781826A1 (en)
WO (1) WO2011064797A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007767B (en) * 2011-07-26 2012-11-19 Φαρματεν Αβεε, Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof.
US10105320B2 (en) * 2013-10-03 2018-10-23 Altria Client Services Soluble fiber lozenge
BG67408B1 (en) * 2019-04-12 2022-01-17 Софарма Ад Oral drug composition with plant alkaloid for treatment of addictions
CN113384536B (en) * 2020-03-14 2024-04-02 鲁南制药集团股份有限公司 Sustained release galanthamine pamoate particles for injection and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2116232A1 (en) * 2008-05-09 2009-11-11 Ratiopharm GmbH Medicine containing galanthamine with controlled release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
CA1326632C (en) 1988-10-26 1994-02-01 Bonnie Davis Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
ES2211215T3 (en) 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. COMPOSITION OF GALANTAMINE CONTROLLED LIBERATION.
US20040097484A1 (en) 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2116232A1 (en) * 2008-05-09 2009-11-11 Ratiopharm GmbH Medicine containing galanthamine with controlled release

Also Published As

Publication number Publication date
WO2011064797A2 (en) 2011-06-03
EP2503996A2 (en) 2012-10-03
CA2781826A1 (en) 2011-06-03
BR112012012766A2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
EP2019665A4 (en) Drug release from nanoparticle-coated capsules
WO2008132712A3 (en) Combination pharmaceutical compositions
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2012022919A3 (en) Nalbuphine-based formulations and uses thereof
WO2007097770A8 (en) Metoprolol succinate e.r. tablets and methods for their preparation
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
USD650833S1 (en) Typeface
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EP2153834A3 (en) Extended release pharmaceutical compositions comprising quetiapine salts
WO2011005052A3 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
EP2241310A3 (en) Modified release formulations of emoxypine
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus
WO2010026467A3 (en) Controlled release tablet of a highly water soluble active agent such as levetiracetam, or citicoline
WO2011064797A3 (en) Controlled release pharmaceutical compositions of galantamine
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
WO2009026257A3 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
PL1994926T3 (en) Valsartan formulations
EP2394644A3 (en) Trimetazidine Formulation With Different Release Profiles
WO2011135581A3 (en) Pharmaceutical compositions of dronedarone
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2781826

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010812951

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012012766

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012012766

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120528